Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy Journal Article
| Authors: | Zelefsky, M. J.; Goldman, D. A.; Hopkins, M.; Pinitpatcharalert, A.; McBride, S.; Gorovets, D.; Ehdaie, B.; Fine, S. W.; Reuter, V. E.; Tyagi, N.; Happersett, L.; Teyateeti, A.; Zhang, Z.; Kollmeier, M. A. |
| Article Title: | Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy |
| Abstract: | Purpose: To investigate predictors associated with post-treatment biopsy outcomes after stereotactic body radiotherapy (SBRT) for localized prostate cancer. Materials and methods: 257 patients treated with prostate SBRT to dose levels of 32.5 Gy to >40 Gy in 5–6 fractions underwent a post-treatment biopsy performed approximately two years after treatment to evaluate local control status. 73 had% intermediate-risk disease (n = 187) and the remaining 17% (n = 43) and 10% (n = 27) had low-risk and high-risk disease, respectively. Results: The incidence of positive, negative, and treatment-effect post-treatment biopsies were 15.6%, 57.6%, and 26.8%, respectively. The incidence of a positive biopsy according to dose was 37.5% (n = 9/24), 21.4% (n = 6/28), 19.4% (n = 6/31), and 10.9% (n = 19/174) for 32.5 Gy, 35 Gy, 37.5 Gy, and >40 Gy, respectively. In a multivariable model, patients treated with SBRT doses of <40 Gy and those with unfavorable-intermediate-risk or high-risk disease had higher likelihood of a positive post-treatment biopsy. A positive post-SBRT biopsy was associated with a significantly higher likelihood of subsequent PSA relapse at five years (Positive biopsy: 57%, 95% CI: 29–77% compared to negative biopsy: 7%, 95% CI: 3–14%; p < 0.001). Conclusion: Based on two-year post-SBRT biopsies, excellent tumor control was achieved when dose levels of 40 Gy or higher were used. Standard SBRT dose levels of 35–37.5 Gy were associated with a higher likelihood of a positive post-treatment biopsy. Two-year positive post-treatment biopsies pre-dated the development of PSA failure in the majority of patients. © 2021 Elsevier B.V. |
| Keywords: | stereotactic body radiotherapy; localized prostate cancer; predictive factors; post-treatment biopsy |
| Journal Title: | Radiotherapy and Oncology |
| Volume: | 159 |
| ISSN: | 0167-8140 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-06-01 |
| Start Page: | 33 |
| End Page: | 38 |
| Language: | English |
| DOI: | 10.1016/j.radonc.2021.02.008 |
| PUBMED: | 33587971 |
| PROVIDER: | scopus |
| PMCID: | PMC10187562 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 May 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work